bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.

bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.